<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>A gentle introduction to group sequential design</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>



<style type="text/css">
code {
white-space: pre;
}
.sourceCode {
overflow: visible;
}
</style>
<style type="text/css" data-origin="pandoc">
html { -webkit-text-size-adjust: 100%; }
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
{ counter-reset: source-line 0; }
pre.numberSource code > span
{ position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
{ content: counter(source-line);
position: relative; left: -1em; text-align: right; vertical-align: baseline;
border: none; display: inline-block;
-webkit-touch-callout: none; -webkit-user-select: none;
-khtml-user-select: none; -moz-user-select: none;
-ms-user-select: none; user-select: none;
padding: 0 4px; width: 4em;
color: #aaaaaa;
}
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa; padding-left: 4px; }
div.sourceCode
{ }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } 
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.at { color: #7d9029; } 
code span.bn { color: #40a070; } 
code span.bu { color: #008000; } 
code span.cf { color: #007020; font-weight: bold; } 
code span.ch { color: #4070a0; } 
code span.cn { color: #880000; } 
code span.co { color: #60a0b0; font-style: italic; } 
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.do { color: #ba2121; font-style: italic; } 
code span.dt { color: #902000; } 
code span.dv { color: #40a070; } 
code span.er { color: #ff0000; font-weight: bold; } 
code span.ex { } 
code span.fl { color: #40a070; } 
code span.fu { color: #06287e; } 
code span.im { color: #008000; font-weight: bold; } 
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } 
code span.kw { color: #007020; font-weight: bold; } 
code span.op { color: #666666; } 
code span.ot { color: #007020; } 
code span.pp { color: #bc7a00; } 
code span.sc { color: #4070a0; } 
code span.ss { color: #bb6688; } 
code span.st { color: #4070a0; } 
code span.va { color: #19177c; } 
code span.vs { color: #4070a0; } 
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } 
</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    var j = 0;
    while (j < rules.length) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") {
        j++;
        continue;
      }
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') {
        j++;
        continue;
      }
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>



<style type="text/css">

div.csl-bib-body { }
div.csl-entry {
clear: both;
margin-bottom: 0em;
}
.hanging div.csl-entry {
margin-left:2em;
text-indent:-2em;
}
div.csl-left-margin {
min-width:2em;
float:left;
}
div.csl-right-inline {
margin-left:2em;
padding-left:1em;
}
div.csl-indent {
margin-left: 2em;
}
</style>

<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">A gentle introduction to group sequential
design</h1>



<div id="introduction" class="section level2">
<h2>Introduction</h2>
<p>This article is intended to give a gentle mathematical and
statistical introduction to group sequential design. We also provide
relatively simple examples from the literature to explain clinical
applications. There is no programming shown, but by accessing the source
for the article all required programming can be accessed; substantial
commenting is provided in the source in the hope that users can
understand how to implement the concepts developed here. Hopefully, the
few mathematical and statistical concepts introduced will not discourage
those wishing to understand some underlying concepts for group
sequential design.</p>
<p>A group sequential design enables repeated analysis of an endpoint
for a clinical trial to enable possible early stopping of a trial for
either a positive result, for futility, or for a safety issue. This
approach can</p>
<ul>
<li>limit exposure risk to patients and clinical trial investment past
the time where known unacceptable safety risks have been established for
the endpoint of interest,</li>
<li>limit investment in a trial where interim results suggest further
evaluation for a positive efficacy finding is futile, or</li>
<li>accelerate the availability of a highly effective treatment by
enabling early approval following an early positive finding.</li>
</ul>
<p>Examples of outcomes that might be considered include:</p>
<ul>
<li>a continuous outcome such as change from baseline at some fixed
follow-up time in the HAM-D depression score,</li>
<li>absolute or difference or risk ratio for a response rate (e.g., in
oncology) or failure rate for a binary (yes/no) outcome, and</li>
<li>a hazard ratio for a time-to-event out such such as time-to-death or
disease progression in an oncology trial or for time until a
cardiovascular event (death, myocardial infarction or unstable
angina).</li>
</ul>
<p>Examples of the above include:</p>
<ul>
<li>a new treatment for major depression where an interim analysis of a
continuous outcome stopped the trial for futility (<span class="citation">Binneman et al. (2008)</span>),</li>
<li>a new treatment for patients with unstable angina undergoing balloon
angioplasty with a positive interim finding for a binary outcome of
death, myocardial infarction or urgent repeat intervention within 30
days (<span class="citation">The CAPTURE Investigators (1997)</span>),
and</li>
<li>a new treatment for patients with lung cancer based on a positive
interim finding for time-to-death (<span class="citation">Gandhi et al.
(2018)</span>).</li>
</ul>
</div>
<div id="group-sequential-design-framework" class="section level2">
<h2>Group sequential design framework</h2>
<p>We assume</p>
<ul>
<li>A two-arm clinical trial with a control and experimental group.</li>
<li>There are <span class="math inline">\(k\)</span> analyses planned
for some integer <span class="math inline">\(k&gt; 1.\)</span></li>
<li>There is a natural parameter <span class="math inline">\(\delta\)</span> describing the underlying
treatment difference with an estimate that has an asymptotically normal
and efficient estimate <span class="math inline">\(\hat\delta_j\)</span>
with variance <span class="math inline">\(\sigma_j^2\)</span> and
corresponding statistical information <span class="math inline">\(\mathcal{I}_j=1/\sigma_j^2\)</span>, at analysis
<span class="math inline">\(j=1,2,\ldots,k\)</span>. A positive value
favoring experimental treatment and negative value favoring control. We
assume a consistent estimate <span class="math inline">\(\hat\sigma_j^2\)</span> of <span class="math inline">\(\sigma_j^2, j=1,2,\ldots,k\)</span>.</li>
<li>The information fraction is defined as <span class="math inline">\(t_j=\mathcal{I}_i/\mathcal{I}_j\)</span> at
analysis <span class="math inline">\(j=1,\ldots,k\)</span>.</li>
<li>Correlations between estimates at different analyses are <span class="math inline">\(\text{Corr}(\hat\delta_i,\hat\delta_j)=\sqrt{\mathcal{I}_i/\mathcal{I}_j}=\sqrt{t_j}\)</span>
for <span class="math inline">\(1\le i\le j\le k.\)</span></li>
<li>There is a test test <span class="math inline">\(Z_j\approx\hat\delta_j/\hat{\sigma}^2_j.\)</span></li>
</ul>
<p>For a time-to-event outcome, <span class="math inline">\(\delta\)</span> would typically represent the
logarithm of the hazard ratio for the control group versus the
experimental group. For a difference in response rates, <span class="math inline">\(\delta\)</span> would represent the underlying
response rates. For a continuous outcome such as the HAM-D, we would
examine the difference in change from baseline at a milestone time point
(e.g., at 6 weeks as in <span class="citation">Binneman et al.
(2008)</span>). For <span class="math inline">\(j=1,\ldots,k\)</span>,
the tests <span class="math inline">\(Z_j\)</span> are asymptotically
multivariate normal with correlations as above, and for <span class="math inline">\(i=1,\ldots,k\)</span> have <span class="math inline">\(\text{Cov}(Z_i,Z_j)=\text{Corr}(\hat\delta_i,\hat\delta_j)\)</span>
and <span class="math inline">\(E(Z_j)=\delta\sqrt{I_j}.\)</span></p>
<p>This multivariate asymptotic normal distribution for <span class="math inline">\(Z_1,\ldots,Z_k\)</span> is referred to as the
<em>canonical form</em> by <span class="citation">Jennison and Turnbull
(2000)</span> who have also summarized much of the surrounding
literature.</p>
</div>
<div id="bounds-for-testing" class="section level2">
<h2>Bounds for testing</h2>
<div id="one-sided-testing" class="section level3">
<h3>One-sided testing</h3>
<p>We assume that the primary test the null hypothesis <span class="math inline">\(H_{0}\)</span>: <span class="math inline">\(\delta=0\)</span> against the alternative <span class="math inline">\(H_{1}\)</span>: <span class="math inline">\(\delta
= \delta_1\)</span> for a fixed effect size <span class="math inline">\(\delta_1 &gt; 0\)</span> which represents a
benefit of experimental treatment compared to control. We assume further
that there is interest in stopping early if there is good evidence to
reject one hypothesis in favor of the other. For <span class="math inline">\(i=1,2,\ldots,k-1\)</span>, interim cutoffs <span class="math inline">\(l_{i}&lt; u_{i}\)</span> are set; final cutoffs
<span class="math inline">\(l_{k}\leq u_{k}\)</span> are also set. For
<span class="math inline">\(i=1,2,\ldots,k\)</span>, the trial is
stopped at analysis <span class="math inline">\(i\)</span> to reject
<span class="math inline">\(H_{0}\)</span> if <span class="math inline">\(l_{j}&lt;Z_{j}&lt; u_{j}\)</span>, <span class="math inline">\(j=1,2,\dots,i-1\)</span> and <span class="math inline">\(Z_{i}\geq u_{i}\)</span>. If the trial continues
until stage <span class="math inline">\(i\)</span>, <span class="math inline">\(H_{0}\)</span> is not rejected at stage <span class="math inline">\(i\)</span>, and <span class="math inline">\(Z_{i}\leq l_{i}\)</span> then <span class="math inline">\(H_{1}\)</span> is rejected in favor of <span class="math inline">\(H_{0}\)</span>, <span class="math inline">\(i=1,2,\ldots,k\)</span>. Thus, <span class="math inline">\(3k\)</span> parameters define a group sequential
design: <span class="math inline">\(l_{i}\)</span>, <span class="math inline">\(u_{i}\)</span>, and <span class="math inline">\(\mathcal{I}_{i}\)</span>, <span class="math inline">\(i=1,2,\ldots,k\)</span>. Note that if <span class="math inline">\(l_{k}&lt; u_{k}\)</span> there is the possibility
of completing the trial without rejecting <span class="math inline">\(H_{0}\)</span> or <span class="math inline">\(H_{1}\)</span>. We will often restrict <span class="math inline">\(l_{k}= u_{k}\)</span> so that one hypothesis is
rejected.</p>
<p>We begin with a one-sided test. In this case there is no interest in
stopping early for a lower bound and thus <span class="math inline">\(l_i= -\infty\)</span>, <span class="math inline">\(i=1,2,\ldots,k\)</span>. The probability of first
crossing an upper bound at analysis <span class="math inline">\(i\)</span>, <span class="math inline">\(i=1,2,\ldots,k\)</span>, is</p>
<p><span class="math display">\[\alpha_{i}^{+}(\delta)=P_{\delta}\{\{Z_{i}\geq
u_{i}\}\cap_{j=1}^{i-1}
\{Z_{j}&lt; u_{j}\}\}\]</span></p>
<p>The Type I error is the probability of ever crossing the upper bound
when <span class="math inline">\(\delta=0\)</span>. The value <span class="math inline">\(\alpha^+_{i}(0)\)</span> is commonly referred to
as the amount of Type I error spent at analysis <span class="math inline">\(i\)</span>, <span class="math inline">\(1\leq
i\leq k\)</span>. The total upper boundary crossing probability for a
trial is denoted in this one-sided scenario by</p>
<p><span class="math display">\[\alpha^+(\delta) \equiv
\sum_{i=1}^{k}\alpha^+_{i}(\delta)\]</span></p>
<p>and the total Type I error by <span class="math inline">\(\alpha^+(0)\)</span>. Assuming <span class="math inline">\(\alpha^+(0)=\alpha\)</span> the design will be
said to provide a one-sided group sequential test at level <span class="math inline">\(\alpha\)</span>.</p>
</div>
<div id="binding" class="section level3">
<h3>Asymmetric two-sided testing</h3>
<p>With both lower and upper bounds for testing and any real value <span class="math inline">\(\delta\)</span> representing treatment effect we
denote the probability of crossing the upper boundary at analysis <span class="math inline">\(i\)</span> without previously crossing a bound
by</p>
<p><span class="math display">\[\alpha_{i}(\delta)=P_{\delta}\{\{Z_{i}\geq
u_{i}\}\cap_{j=1}^{i-1}
\{ l_{j}&lt;Z_{j}&lt; u_{j}\}\},\]</span></p>
<p><span class="math inline">\(i=1,2,\ldots,k.\)</span> The total
probability of crossing an upper bound prior to crossing a lower bound
is denoted by</p>
<p><span class="math display">\[\alpha(\delta)\equiv\sum_{i=1}^{k}\alpha_{i}(\delta).\]</span></p>
<p>Next, we consider analogous notation for the lower bound. For <span class="math inline">\(i=1,2,\ldots,k\)</span> denote the probability of
crossing a lower bound at analysis <span class="math inline">\(i\)</span> without previously crossing any bound
by <span class="math display">\[\beta_{i}(\delta)=P_{\delta}\{\{Z_{i}\leq
l_{i}\}\cap_{j=1}^{i-1}\{ l_{j}
&lt;Z_{j}&lt; u_{j}\}\}.\]</span> The total lower boundary crossing
probability in this case is written as <span class="math display">\[\beta(\delta)=
{\sum\limits_{i=1}^{k}}
\beta_{i}(\delta).\]</span></p>
<p>When a design has final bounds equal (<span class="math inline">\(l_k=u_k\)</span>), <span class="math inline">\(\beta(\delta_1)\)</span> is the Type II error
which is equal to 1 minus the power of the design. In this case, <span class="math inline">\(\beta_i(\delta)\)</span> is referred to as the
<span class="math inline">\(\beta\)</span>-spending at analysis <span class="math inline">\(i, i=1,\ldots,k\)</span>.</p>
</div>
</div>
<div id="spending-function-design" class="section level2">
<h2>Spending function design</h2>
<p>Type I error is most often defined with <span class="math inline">\(\alpha_i^+(0), i=1,\ldots,k\)</span>. This is
referred to as non-binding Type I error since any lower bound is ignored
in the calculation. This means that if a trial is continued in spite of
a lower bound being crossed at an interim analysis that Type I error is
still controlled at the design <span class="math inline">\(\alpha\)</span>-level. For Phase III trials used
for approvals of new treatments, non-binding Type I error calculation is
generally expected by regulators.</p>
<p>For any given <span class="math inline">\(0&lt;\alpha&lt;1\)</span>
we define a non-decreasing <span class="math inline">\(\alpha\)</span>-spending function <span class="math inline">\(f(t; \alpha)\)</span> for <span class="math inline">\(t\geq 0\)</span> with <span class="math inline">\(\alpha\left(  0\right)  =0\)</span> and for <span class="math inline">\(t\geq 1\)</span>, <span class="math inline">\(f(
t; \alpha)  =\alpha\)</span>. Letting <span class="math inline">\(t_0=0\)</span>, we set <span class="math inline">\(\alpha_j(0)\)</span> for <span class="math inline">\(j=1,\ldots,k\)</span> through the equation <span class="math display">\[\alpha^+_{j}(0) = f(t_j;\alpha)-f(t_{j-1};
\alpha).\]</span> Assuming an asymmetric lower bound, we similarly use a
<span class="math inline">\(\beta\)</span>-spending function and to set
<span class="math inline">\(\beta\)</span>-spending at analysis <span class="math inline">\(j=1,\ldots, k\)</span> as: <span class="math display">\[\beta_{j}(\delta_1) = g(t_j;\delta_1, \beta) -
g(t_{j-1};\delta_1, \beta).\]</span></p>
<p>In the following example, the function <span class="math inline">\(\Phi()\)</span> represents the cumulative
distribution function for the standard normal distribution function
(i.e., mean 0, standard deviation 1). The major depression study of
<span class="citation">Binneman et al. (2008)</span> considered above
used the <span class="citation">Lan and DeMets (1983)</span> spending
function approximating an O’Brien-Fleming bound for a single interim
analysis half way through the trial with</p>
<p><span class="math display">\[f(t; \alpha) =
2\left(  1-\Phi\left(  \frac{\Phi
^{-1}(\alpha/2)}{\sqrt{t}}\right)  \right).\]</span></p>
<p><span class="math display">\[g(t; \beta) =
2\left(  1-\Phi\left(  \frac{\Phi
^{-1}(\beta/2)}{\sqrt{t}}\right)  \right).\]</span></p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" tabindex="-1"></a><span class="fu">library</span>(gsDesign)</span></code></pre></div>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" tabindex="-1"></a>delta1 <span class="ot">&lt;-</span> <span class="dv">3</span> <span class="co"># Treatment effect, alternate hypothesis</span></span>
<span id="cb2-2"><a href="#cb2-2" tabindex="-1"></a>delta0 <span class="ot">&lt;-</span> <span class="dv">0</span> <span class="co"># Treatment effect, null hypothesis</span></span>
<span id="cb2-3"><a href="#cb2-3" tabindex="-1"></a>ratio <span class="ot">&lt;-</span> <span class="dv">1</span> <span class="co"># Randomization ratio (experimental / control)</span></span>
<span id="cb2-4"><a href="#cb2-4" tabindex="-1"></a>sd <span class="ot">&lt;-</span> <span class="fl">7.5</span> <span class="co"># Standard deviation for change in HAM-D score</span></span>
<span id="cb2-5"><a href="#cb2-5" tabindex="-1"></a>alpha <span class="ot">&lt;-</span> <span class="fl">0.1</span> <span class="co"># 1-sided Type I error</span></span>
<span id="cb2-6"><a href="#cb2-6" tabindex="-1"></a>beta <span class="ot">&lt;-</span> <span class="fl">0.17</span> <span class="co"># Targeted Type II error (1 - targeted power)</span></span>
<span id="cb2-7"><a href="#cb2-7" tabindex="-1"></a>k <span class="ot">&lt;-</span> <span class="dv">2</span> <span class="co"># Number of planned analyses</span></span>
<span id="cb2-8"><a href="#cb2-8" tabindex="-1"></a>test.type <span class="ot">&lt;-</span> <span class="dv">4</span> <span class="co"># Asymmetric bound design with non-binding futility bound</span></span>
<span id="cb2-9"><a href="#cb2-9" tabindex="-1"></a>timing <span class="ot">&lt;-</span> .<span class="dv">5</span> <span class="co"># information fraction at interim analyses</span></span>
<span id="cb2-10"><a href="#cb2-10" tabindex="-1"></a>sfu <span class="ot">&lt;-</span> sfLDOF <span class="co"># O&#39;Brien-Fleming spending function for alpha-spending</span></span>
<span id="cb2-11"><a href="#cb2-11" tabindex="-1"></a>sfupar <span class="ot">&lt;-</span> <span class="dv">0</span> <span class="co"># Parameter for upper spending function</span></span>
<span id="cb2-12"><a href="#cb2-12" tabindex="-1"></a>sfl <span class="ot">&lt;-</span> sfLDOF <span class="co"># O&#39;Brien-Fleming spending function for beta-spending</span></span>
<span id="cb2-13"><a href="#cb2-13" tabindex="-1"></a>sflpar <span class="ot">&lt;-</span> <span class="dv">0</span> <span class="co"># Parameter for lower spending function</span></span>
<span id="cb2-14"><a href="#cb2-14" tabindex="-1"></a>delta <span class="ot">&lt;-</span> <span class="dv">0</span></span>
<span id="cb2-15"><a href="#cb2-15" tabindex="-1"></a>endpoint <span class="ot">&lt;-</span> <span class="st">&quot;normal&quot;</span></span></code></pre></div>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" tabindex="-1"></a><span class="co"># Derive normal fixed design sample size</span></span>
<span id="cb3-2"><a href="#cb3-2" tabindex="-1"></a>n <span class="ot">&lt;-</span> <span class="fu">nNormal</span>(</span>
<span id="cb3-3"><a href="#cb3-3" tabindex="-1"></a>  <span class="at">delta1 =</span> delta1,</span>
<span id="cb3-4"><a href="#cb3-4" tabindex="-1"></a>  <span class="at">delta0 =</span> delta0,</span>
<span id="cb3-5"><a href="#cb3-5" tabindex="-1"></a>  <span class="at">ratio =</span> ratio,</span>
<span id="cb3-6"><a href="#cb3-6" tabindex="-1"></a>  <span class="at">sd =</span> sd,</span>
<span id="cb3-7"><a href="#cb3-7" tabindex="-1"></a>  <span class="at">alpha =</span> alpha,</span>
<span id="cb3-8"><a href="#cb3-8" tabindex="-1"></a>  <span class="at">beta =</span> beta</span>
<span id="cb3-9"><a href="#cb3-9" tabindex="-1"></a>)</span></code></pre></div>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" tabindex="-1"></a><span class="co"># Derive group sequential design based on parameters above</span></span>
<span id="cb4-2"><a href="#cb4-2" tabindex="-1"></a>x <span class="ot">&lt;-</span> <span class="fu">gsDesign</span>(</span>
<span id="cb4-3"><a href="#cb4-3" tabindex="-1"></a>  <span class="at">k =</span> k,</span>
<span id="cb4-4"><a href="#cb4-4" tabindex="-1"></a>  <span class="at">test.type =</span> test.type,</span>
<span id="cb4-5"><a href="#cb4-5" tabindex="-1"></a>  <span class="at">alpha =</span> alpha,</span>
<span id="cb4-6"><a href="#cb4-6" tabindex="-1"></a>  <span class="at">beta =</span> beta,</span>
<span id="cb4-7"><a href="#cb4-7" tabindex="-1"></a>  <span class="at">timing =</span> timing,</span>
<span id="cb4-8"><a href="#cb4-8" tabindex="-1"></a>  <span class="at">sfu =</span> sfu,</span>
<span id="cb4-9"><a href="#cb4-9" tabindex="-1"></a>  <span class="at">sfupar =</span> sfupar,</span>
<span id="cb4-10"><a href="#cb4-10" tabindex="-1"></a>  <span class="at">sfl =</span> sfl,</span>
<span id="cb4-11"><a href="#cb4-11" tabindex="-1"></a>  <span class="at">sflpar =</span> sflpar,</span>
<span id="cb4-12"><a href="#cb4-12" tabindex="-1"></a>  <span class="at">delta =</span> delta, <span class="co"># Not used since n.fix is provided</span></span>
<span id="cb4-13"><a href="#cb4-13" tabindex="-1"></a>  <span class="at">delta1 =</span> delta1,</span>
<span id="cb4-14"><a href="#cb4-14" tabindex="-1"></a>  <span class="at">delta0 =</span> delta0,</span>
<span id="cb4-15"><a href="#cb4-15" tabindex="-1"></a>  <span class="at">endpoint =</span> <span class="st">&quot;normal&quot;</span>,</span>
<span id="cb4-16"><a href="#cb4-16" tabindex="-1"></a>  <span class="at">n.fix =</span> n</span>
<span id="cb4-17"><a href="#cb4-17" tabindex="-1"></a>)</span>
<span id="cb4-18"><a href="#cb4-18" tabindex="-1"></a><span class="co"># Convert sample size at each analysis to integer values</span></span>
<span id="cb4-19"><a href="#cb4-19" tabindex="-1"></a>x <span class="ot">&lt;-</span> <span class="fu">toInteger</span>(x)</span></code></pre></div>
<pre><code>#&gt; toInteger: rounding done to nearest integer since ratio was not specified as postive integer .</code></pre>
<p>The planned design used <span class="math inline">\(\alpha=0.1\)</span>, one-sided and Type II error
17% (83% power) with an interim analysis at 50% of the final planned
observations. This leads to Type I <span class="math inline">\(\alpha\)</span>-spending of 0.02 and <span class="math inline">\(\beta\)</span>-spending of 0.052 at the planned
interim. An advantage of the spending function approach is that bounds
can be adjusted when the number of observations at analyses are
different than planned. The actual observations for experimental versus
control at the analysis were 59 as opposed to the planned 67, which
resulted in interim spending fraction <span class="math inline">\(t_1=\)</span> 0.4403. With the Lan-DeMets spending
function to approximate O’Brien-Fleming bounds this results in <span class="math inline">\(\alpha\)</span>-spending of 0.0132
(<code>P(Cross) if delta=0</code> row in Efficacy column) and <span class="math inline">\(\beta\)</span>-spending of 0.0386
(<code>P(Cross) if delta=3</code> row in Futility column). We note that
the Z-value and 1-sided p-values in the table below correspond exactly
and either can be used for evaluation of statistical significance for a
trial result. The rows labeled <code>~delta at bound</code> are
approximations that describe approximately what treatment difference is
required to cross a bound; these should not be used for a formal
evaluation of whether a bound has been crossed. The O’Brien-Fleming
spending function is generally felt to provide conservative bounds for
stopping at interim analysis. Most of the error spending is reserved for
the final analysis in this example. The futility bound only required a
small trend in the wrong direction to stop the trial; a nominal p-value
of 0.77 was observed which crossed the futility bound, stopping the
trial since this was greater than the futility p-value bound of 0.59.
Finally, we note that at the final analysis, the cumulative probability
for <code>P(Cross) if delta=0</code> is less than the planned <span class="math inline">\(\alpha=0.10\)</span>. This probability represents
<span class="math inline">\(\alpha(0)\)</span> which excludes the
probability of crossing the lower bound at the interim analysis and the
final analysis. The value of the non-binding Type I error is still <span class="math inline">\(\alpha^+(0) = 0.10\)</span>.</p>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" tabindex="-1"></a><span class="co"># Updated alpha is unchanged</span></span>
<span id="cb6-2"><a href="#cb6-2" tabindex="-1"></a>alphau <span class="ot">&lt;-</span> <span class="fl">0.1</span></span>
<span id="cb6-3"><a href="#cb6-3" tabindex="-1"></a><span class="co"># Updated sample size at each analysis</span></span>
<span id="cb6-4"><a href="#cb6-4" tabindex="-1"></a>n.I <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="dv">59</span>, <span class="dv">134</span>)</span>
<span id="cb6-5"><a href="#cb6-5" tabindex="-1"></a><span class="co"># Updated number of analyses</span></span>
<span id="cb6-6"><a href="#cb6-6" tabindex="-1"></a>ku <span class="ot">&lt;-</span> <span class="fu">length</span>(n.I)</span>
<span id="cb6-7"><a href="#cb6-7" tabindex="-1"></a><span class="co"># Information fraction is used for spending</span></span>
<span id="cb6-8"><a href="#cb6-8" tabindex="-1"></a>usTime <span class="ot">&lt;-</span> n.I <span class="sc">/</span> x<span class="sc">$</span>n.I[x<span class="sc">$</span>k]</span>
<span id="cb6-9"><a href="#cb6-9" tabindex="-1"></a>lsTime <span class="ot">&lt;-</span> usTime</span></code></pre></div>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" tabindex="-1"></a><span class="co"># Update design based on actual interim sample size and planned final sample size</span></span>
<span id="cb7-2"><a href="#cb7-2" tabindex="-1"></a>xu <span class="ot">&lt;-</span> <span class="fu">gsDesign</span>(</span>
<span id="cb7-3"><a href="#cb7-3" tabindex="-1"></a>  <span class="at">k =</span> ku,</span>
<span id="cb7-4"><a href="#cb7-4" tabindex="-1"></a>  <span class="at">test.type =</span> test.type,</span>
<span id="cb7-5"><a href="#cb7-5" tabindex="-1"></a>  <span class="at">alpha =</span> alphau,</span>
<span id="cb7-6"><a href="#cb7-6" tabindex="-1"></a>  <span class="at">beta =</span> x<span class="sc">$</span>beta,</span>
<span id="cb7-7"><a href="#cb7-7" tabindex="-1"></a>  <span class="at">sfu =</span> sfu,</span>
<span id="cb7-8"><a href="#cb7-8" tabindex="-1"></a>  <span class="at">sfupar =</span> sfupar,</span>
<span id="cb7-9"><a href="#cb7-9" tabindex="-1"></a>  <span class="at">sfl =</span> sfl,</span>
<span id="cb7-10"><a href="#cb7-10" tabindex="-1"></a>  <span class="at">sflpar =</span> sflpar,</span>
<span id="cb7-11"><a href="#cb7-11" tabindex="-1"></a>  <span class="at">n.I =</span> n.I,</span>
<span id="cb7-12"><a href="#cb7-12" tabindex="-1"></a>  <span class="at">maxn.IPlan =</span> x<span class="sc">$</span>n.I[x<span class="sc">$</span>k],</span>
<span id="cb7-13"><a href="#cb7-13" tabindex="-1"></a>  <span class="at">delta =</span> x<span class="sc">$</span>delta,</span>
<span id="cb7-14"><a href="#cb7-14" tabindex="-1"></a>  <span class="at">delta1 =</span> x<span class="sc">$</span>delta1,</span>
<span id="cb7-15"><a href="#cb7-15" tabindex="-1"></a>  <span class="at">delta0 =</span> x<span class="sc">$</span>delta0,</span>
<span id="cb7-16"><a href="#cb7-16" tabindex="-1"></a>  <span class="at">endpoint =</span> endpoint,</span>
<span id="cb7-17"><a href="#cb7-17" tabindex="-1"></a>  <span class="at">n.fix =</span> n,</span>
<span id="cb7-18"><a href="#cb7-18" tabindex="-1"></a>  <span class="at">usTime =</span> usTime,</span>
<span id="cb7-19"><a href="#cb7-19" tabindex="-1"></a>  <span class="at">lsTime =</span> lsTime</span>
<span id="cb7-20"><a href="#cb7-20" tabindex="-1"></a>)</span></code></pre></div>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" tabindex="-1"></a><span class="co"># Summarize bounds</span></span>
<span id="cb8-2"><a href="#cb8-2" tabindex="-1"></a><span class="fu">gsBoundSummary</span>(xu, <span class="at">Nname =</span> <span class="st">&quot;N&quot;</span>, <span class="at">digits =</span> <span class="dv">4</span>, <span class="at">ddigits =</span> <span class="dv">2</span>, <span class="at">tdigits =</span> <span class="dv">1</span>)</span></code></pre></div>
<pre><code>#&gt;   Analysis               Value Efficacy Futility
#&gt;  IA 1: 44%                   Z   2.2209  -0.2304
#&gt;      N: 59         p (1-sided)   0.0132   0.5911
#&gt;                ~delta at bound   4.3370  -0.4500
#&gt;            P(Cross) if delta=0   0.0132   0.4089
#&gt;            P(Cross) if delta=3   0.2468   0.0386
#&gt;      Final                   Z   1.3047   1.3047
#&gt;     N: 134         p (1-sided)   0.0960   0.0960
#&gt;                ~delta at bound   1.6907   1.6907
#&gt;            P(Cross) if delta=0   0.0965   0.9035
#&gt;            P(Cross) if delta=3   0.8350   0.1650</code></pre>
</div>
<div id="references" class="section level2 unnumbered">
<h2 class="unnumbered">References</h2>
<div id="refs" class="references csl-bib-body hanging-indent" entry-spacing="0">
<div id="ref-binneman20086" class="csl-entry">
Binneman, Brendon, Douglas Feltner, Sheela Kolluri, Yuanjun Shi, Ruolun
Qiu, and Thomas Stiger. 2008. <span>“A 6-Week Randomized,
Placebo-Controlled Trial of <span>CP-316,311</span> (a Selective <span class="math inline">\({CRH}_{1}\)</span> Antagonist) in the Treatment of
Major Depression.”</span> <em>American Journal of Psychiatry</em> 165
(5): 617–20.
</div>
<div id="ref-KEYNOTE189" class="csl-entry">
Gandhi, Leena, Delvys Rodrı́guez-Abreu, Shirish Gadgeel, Emilio Esteban,
Enriqueta Felip, Flávia De Angelis, Manuel Domine, et al. 2018.
<span>“Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung
Cancer.”</span> <em>New England Journal of Medicine</em> 378 (22):
2078–92.
</div>
<div id="ref-JTBook" class="csl-entry">
Jennison, Christopher, and Bruce W. Turnbull. 2000. <em>Group Sequential
Methods with Applications to Clinical Trials</em>. Boca Raton, FL:
Chapman; Hall/CRC.
</div>
<div id="ref-LanDeMets" class="csl-entry">
Lan, K. K. G., and David L. DeMets. 1983. <span>“Discrete Sequential
Boundaries for Clinical Trials.”</span> <em>Biometrika</em> 70: 659–63.
</div>
<div id="ref-CAPTURE" class="csl-entry">
The CAPTURE Investigators. 1997. <span>“Randomized Placebo-Controlled
Trial of Abciximab Before and During Coronary Intervention in Refractory
Unstable Angina: The <span>CAPTURE</span> Study.”</span> <em>Lancet</em>
349 (9063): 1429–35.
</div>
</div>
</div>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
